Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
Trial · NCT01712308
Adverse events134
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 134
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction | Immune system disorders | Treatment Monotherapy (Sotatercept) | 0 | 35 | 0 |
| other | Allergic reaction | Immune system disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 1 | 21 | 1 |
| other | Cardiac disorders | Cardiac disorders | Treatment Monotherapy (Sotatercept) | 5 | 35 | 7 |
| other | Cardiac disorders | Cardiac disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 5 | 21 | 5 |
| other | Constipation | Gastrointestinal disorders | Treatment Monotherapy (Sotatercept) | 5 | 35 | 5 |
| other | Constipation | Gastrointestinal disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 5 | 21 | 5 |
| other | Diarrhea | Gastrointestinal disorders | Treatment Monotherapy (Sotatercept) | 9 | 35 | 9 |
| other | Diarrhea | Gastrointestinal disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 8 | 21 | 8 |
| other | Dizziness | Nervous system disorders | Treatment Monotherapy (Sotatercept) | 6 | 35 | 8 |
| other | Dizziness | Nervous system disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 4 | 21 | 5 |
| other | Dysphagia | Gastrointestinal disorders | Treatment Monotherapy (Sotatercept) | 0 | 35 | 0 |
| other | Dysphagia | Gastrointestinal disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 2 | 21 | 2 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment Monotherapy (Sotatercept) | 6 | 35 | 6 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 3 | 21 | |
| other | Edema limbs | General disorders | Treatment Monotherapy (Sotatercept) | 9 | 35 | 9 |
| other | Edema limbs | General disorders | Treatment Combination (Ruxolitinib + Sotatercept) | 3 | 21 | 3 |
| other | Elevated Albumin/Creatinine Ratio | Investigations | Treatment Monotherapy (Sotatercept) | 4 | 35 | 4 |
| other | Elevated Albumin/Creatinine Ratio | Investigations | Treatment Combination (Ruxolitinib + Sotatercept) | 1 | 21 | 1 |
| other | elevated transaminase levels | Investigations | Treatment Monotherapy (Sotatercept) | 1 | 35 | 2 |
| other | elevated transaminase levels | Investigations | Treatment Combination (Ruxolitinib + Sotatercept) | 3 | 21 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01712308/events